Mirus Bio, founded in 1995 and headquartered in Madison, Wisconsin, specializes in developing and manufacturing transfection reagents and related technologies for nucleic acid delivery. In 2024, Merck KGaA (dba MilliporeSigma in the U.S. and Canada) acquired Mirus Bio for $600 million, aiming to advance its integrated offerings in viral vector manufacturing. Mirus Bio's products facilitate gene expression, biotherapeutic protein production, virus manufacturing, and genome editing.